Early Access Program in Europe and financing of European subsidiary

Situation

• Our client, a publicly listed North American chemistry-based biotech, required support on a range of key European strategic issues related to the commercialization of its leading phase III product (oncology):

1. Potential of a European Early Access Program (EAP)
2. Structure and cost of minimal European infrastructure to support development
3. Feasibility of raising ring-fenced finance to fund European launch

Bionest Contribution

• Pan-European EAP feasibility study including KOL interviews, financial modeling and roll-out plan
• Preliminary European roll-out plan
• Analysis of financing solutions, and identification of potential investors

Key Results

• Detailed understanding of European regulatory, operational and related financial issues
• European EAP structured to meet client needs